Is the price fair?
What IQV's price assumes
IQVIA trades at 32.5× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
32.5
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 1.74
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.6%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +0.16%
Growth the price implies · The price pays for +0.16% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.
Details›
- Price / book2026-Q1
- 4.65
- EV / EBIT2026-Q1
- 18.6
- EV / sales2026-Q1
- 2.47
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $2.12B
- Market capitalisation
- $28.0B
- 3-year revenue growth
- +4.7%
- 3-year free cash flow growth
- +12%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $276.82 |
| Its own P/E history, median | $394.06 |
| Its own P/E history, upper quartile | $912.47 |
| 52-week range | $156.66 – $261.57 |
| Today | $261.57 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #11 of 29 by Smart Score